Bristol-Myers Squibb Company (BMY)

Return on assets (ROA)

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Net income (ttm)	US$ in thousands	-8,948,000	-7,258,000	-6,541,000	-6,148,000	8,025,000	8,285,000	7,963,000	7,311,000	6,327,000	6,677,000	6,617,000	6,251,000	6,994,000	-5,405,000	-5,079,000	-6,219,000	-9,015,000	-44,000	-563,000	954,000
Total assets	US$ in thousands	92,603,000	93,670,000	94,646,000	99,031,000	95,159,000	91,263,000	93,489,000	94,281,000	96,820,000	98,196,000	100,357,000	103,034,000	109,314,000	110,893,000	110,797,000	112,435,000	118,481,000	125,536,000	128,076,000	129,285,000
ROA		-9.66%	-7.75%	-6.91%	-6.21%	8.43%	9.08%	8.52%	7.75%	6.53%	6.80%	6.59%	6.07%	6.40%	-4.87%	-4.58%	-5.53%	-7.61%	-0.04%	-0.44%	0.74%

December 31, 2024 calculation

ROA = Net income (ttm) ÷ Total assets
= $-8,948,000K ÷ $92,603,000K
= -9.66%

Bristol-Myers Squibb Company's return on assets (ROA) has shown fluctuating performance over the past several quarters. The ROA started positively at 0.74% in March 2020, but then turned negative in the following quarters, reaching a low of -9.66% by December 2024.

Despite the negative trend in the earlier years, the company managed to improve its ROA significantly in the subsequent quarters, with values ranging from 6.07% to 9.08% towards the end of 2023. However, the ROA dipped once again into negative territory in the first half of 2024, displaying a concerning decline.

It is essential for Bristol-Myers Squibb Company to closely monitor and analyze the factors contributing to the fluctuations in its ROA to ensure sustained profitability and efficiency in asset utilization. Continued efforts to improve operational performance and optimize asset management will be crucial to enhance ROA in the future.